The government shutdown has dragged on for weeks, and there seems to be no resolution in sight. While there’s a lot of chatter around Affordable Care Act subsidies, one of the crucial, yet unanswered, questions lingers: how is that money actually being spent?
It’s a tough question to tackle because there’s still a significant lack of price transparency in U.S. healthcare.
In 2024, the federal government allocated around $125 billion for Affordable Care Act grants. According to the Congressional Budget Office, spending on these grants is projected to surpass $1 trillion over the next decade. Those figures are far higher than what was initially estimated, and rising premiums might play a role. Benchmark plan premiums have seen an increase of 70 to 90 percent in the last ten years. It’s thought that competition among health insurance exchanges might help suppress these rises, but without functioning markets, all parties—governments, businesses, and patients—lose out on the benefits of competition. The absence of real, confirmable prices means the market can’t truly operate.
The Affordable Care Act was pitched as a way to assist families in purchasing insurance, but it has ended up essentially ensuring steady revenue for insurance providers. Most markets are still controlled by a limited number of insurance companies. The subsidies go directly to insurers based on a percentage of premiums, instead of a flat voucher system, creating millions of new insured individuals—customers for these companies. They, in turn, raised their rates, knowing taxpayers would cover the differences.
So, why have insurance premiums gone up since the inception of Obamacare? One might cynically suggest greed, but there are several plausible theories, albeit difficult to quantify. Some believe that because subsidies increase with premiums, there’s less incentive for insurers to keep prices in check. Insurers often cite rising costs in hospitals and medications, mergers among health systems, and more high-cost enrollees.
While these points hold some weight, the core issue is still that we can’t assert anything with certainty.
Federal regulations require insurers and hospitals to disclose negotiated prices, but compliance has largely been driven by performance metrics. Insurers post a plethora of “machine-readable” files that aren’t user-friendly, making it hard for anyone—patients, employers, or policymakers—to really grasp the basic question: what does healthcare actually cost?
Families are understandably anxious about potential hikes in their insurance costs. However, we need to balance this concern with the reality that we’re spending billions annually propping up a broken system. Ironically, the primary beneficiaries of taxpayer funding aren’t the hospitals, doctors, or patients, but rather the insurance companies.
If Congress chooses to extend the Affordable Care Act subsidies that families depend on, there should be a requirement for genuine price transparency in return. Reporting should be mandatory and easy to understand, detailing what insurers will pay for care and what patients will owe. The public has a right to know how much of the subsidy actually goes toward premiums and patient care versus administrative costs or executive bonuses. Taxpayers deserve to see where their money is going.
Concern for families dealing with rising costs doesn’t negate the need for fiscal responsibility. Yet, the ongoing debate about healthcare expenses often spotlighting smaller household costs overlooks the larger sums the federal government dispenses to insurance companies without any meaningful transparency or accountability.
Congress has the option to continue funding a system that remains costly and opaque or embrace the chance to implement necessary changes that should have been made long ago. If insurance companies expect taxpayer funding, then those taxpayers should be able to see exactly what they’re being charged.
